NCT03349983View on ClinicalTrials.gov

Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 8, 2018

Primary Completion Date

June 13, 2020

Study Completion Date

June 13, 2020

Conditions
Safety Issues
Interventions
BIOLOGICAL

MVA-BN-Brachyury/ FPV-Brachyury

Two priming doses of MVA-BN-Brachyury followed by boost doses of FPV-Brachyury monthly for 6 months

Trial Locations (1)

20892

Genitourinary Malignancies Branch National Cancer Institute, Bethesda

Sponsors

Lead Sponsor

Bavarian Nordic
All Listed Sponsors
lead

Bavarian Nordic

INDUSTRY

NCT03349983 - Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury) | Biotech Hunter | Biotech Hunter